Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:GLMDNASDAQ:OTICNASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.60-6.5%$0.96$4.30▼$658.60$37.30M6.0671,389 shs136,053 shsGLMDGalmed Pharmaceuticals$1.36-8.1%$1.41$1.15▼$23.80$2.25M0.491.29 million shs236,848 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASILOSilo Pharma$0.46+3.1%$0.92$0.41▼$4.50$2.06M0.372.21 million shs257,651 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-6.50%+1,110.53%+651.63%+28.13%-99.54%GLMDGalmed Pharmaceuticals-8.11%-0.73%-18.56%-37.04%-69.55%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SILOSilo Pharma+3.15%+3.03%-45.36%-66.74%-76.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.1411 of 5 stars3.54.00.00.02.10.00.6GLMDGalmed Pharmaceuticals0.8748 of 5 stars0.02.00.00.03.02.50.6OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ASILOSilo Pharma0.2732 of 5 stars0.02.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$10,952.00237,986.96% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/AOTICOtonomy 0.00N/AN/AN/ASILOSilo Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, GLMD, APVO, and SILO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M11.99N/AN/A$3.26 per share1.41GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01SILOSilo Pharma$72.10K28.55N/AN/A$2.14 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)GLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ASILOSilo Pharma-$3.70M-$1.17N/A∞N/A-5,255.05%-61.38%-47.49%8/11/2025 (Estimated)Latest OTIC, GLMD, APVO, and SILO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/15/2025Q1 2025APVOAptevo Therapeutics-$4.21-$4.39-$0.18-$4.39N/AN/A5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 million3/28/2025Q4 2024SILOSilo PharmaN/A-$0.41N/A-$0.41N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A1.721.72GLMDGalmed PharmaceuticalsN/A7.037.03OTICOtonomyN/A1.741.74SILOSilo PharmaN/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%GLMDGalmed Pharmaceuticals76.14%OTICOtonomy41.23%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%GLMDGalmed Pharmaceuticals19.80%OTICOtonomy1.09%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics508.11 million1.46 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionableOTICOtonomy5168.53 million67.78 millionOptionableSILOSilo Pharma24.48 million4.29 millionNot OptionableOTIC, GLMD, APVO, and SILO HeadlinesRecent News About These CompaniesSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deSilo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drugMay 21, 2025 | msn.comSilo Pharma, Inc. Partners with Resyca BV for SPC-15 Drug-Device Study Aimed at PTSD TreatmentMay 21, 2025 | quiverquant.comSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 21, 2025 | globenewswire.comSilo Pharma, Inc.: Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 16, 2025 | finanznachrichten.deSilo Pharma Signs With Frontage Labs For FDA Requested Safety Study Of SPC-15May 16, 2025 | nasdaq.comSilo Pharma Announces Closing of $2 Million Public OfferingMay 16, 2025 | globenewswire.comSilo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD TreatmentMay 16, 2025 | msn.comSilo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated WarrantsMay 15, 2025 | quiverquant.comSilo Pharma Announces Pricing of $2 Million Public OfferingMay 15, 2025 | globenewswire.comSilo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 14, 2025 | globenewswire.comSilo Pharma, Inc. Announces Agreement with Frontage Laboratories for SPC-15 Safety and Toxicology Study Targeting PTSD TreatmentMay 14, 2025 | quiverquant.comSilo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage LaboratoriesMay 14, 2025 | globenewswire.comCounterproposal to Swiss cost-cutting initiativeMay 12, 2025 | thepharmaletter.comSilo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | finance.yahoo.comSilo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | globenewswire.comSilo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of ActionApril 29, 2025 | nasdaq.comSarasota company applies for Alzheimer's drug patentApril 29, 2025 | businessobserverfl.comSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s DrugApril 28, 2025 | finance.yahoo.comSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's DrugApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveBy Nathan Reiff | May 23, 2025View NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the WaveSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?OTIC, GLMD, APVO, and SILO Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.60 -0.32 (-6.50%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.58 -0.02 (-0.54%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Galmed Pharmaceuticals NASDAQ:GLMD$1.36 -0.12 (-8.11%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.39 +0.03 (+2.21%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Silo Pharma NASDAQ:SILO$0.46 +0.01 (+3.15%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.45 -0.01 (-1.96%) As of 05:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
